Download Image
    
Share
  
Post
Posaconazole for COVID-19
1 study with 249 patients
Hospital Icon Control
Hospital Icon Posaconazole Serious Outcome Risk
COVID-19 Posaconazole studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -131% Mortality -131% Prophylaxis -131% Favorsposaconazole Favorscontrol
Jan 12
 Prattes et al., Mycoses, doi:10.1111/myc.70023 Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study (POSACOVID)
131% higher mortality (p<0.0001) and 54% improvement (p=0.41). Prospective matched case-control study of 249 mechanically ventilated COVID-19 patients in Europe, showing variable impact of posaconazole prophylaxis on COVID-19-associated pulmonary aspergillosis (CAPA) incidence depending on baseline C..